Don't Yet Rely on Bezlotoxumab to Lower Risk of Recurrent C. diff Diarrhea

February 2017

You'll hear about bezlotoxumab (Zinplava, zin-PLAH-vah), the first drug approved to prevent DIARRHEA recurrence due to Clostridium difficile.

Around one in 4 patients will have a recurrence of C. diff diarrhea after the first episode...and 2 in 3 after the second episode.

Bezlotoxumab is a monoclonal antibody that binds to C. diff's toxin B...to keep its diarrhea-causing effects from returning.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote